Early Briefing and Review: Gilead Sciences, InterMune, NPS Pharma, and
LONDON, August 6, 2013
LONDON, August 6, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Monday, August 5, 2013, the S&P 500 closed 0.15% lower at 1,707.14. Shares
in biotechnology companies ended on a mixed note as the broader market edged
lower. The major movers in the sector included Gilead Sciences Inc. (NASDAQ:
GILD), InterMune Inc. (NASDAQ: ITMN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP),
and Halozyme Therapeutics Inc. (NASDAQ: HALO). AAAResearchReports.com has
released free charting and technical research on these aforementioned
companies. Register to read these reports at:
Shares in Gilead Sciences Inc. fell sharply on Monday as the broader market
declined. The company's shares ended the day 1.30% lower at $60.95 after
fluctuating between $60.43 and $61.90. A total of 6.11 million shares were
traded, which is below the daily average volume of 11.01 million. Gilead
Sciences' shares have declined 0.73% in the last three trading sessions.
Nevertheless, Gilead Sciences' stock is trading above its 50-day and 200-day
moving averages. Sign up for free report on GILD at:
InterMune Inc.'s stock closed slightly lower on Monday as the broader market
ended on a declining note. The company's shares fluctuated between $15.49 and
$15.90 before finishing the day 0.89% lower at $15.52. A total of 1.10 million
shares were traded, which is below the daily average volume of 1.43 million.
Despite Monday's pullback, InterMune's shares have gained 0.06% in the last
three trading sessions. ITMN free technical report can be accessed by signing
Shares in NPS Pharmaceuticals Inc. edged higher on Monday, extending their
gains from previous trading sessions. The company's shares oscillated between
$18.55 and $19.06 before finishing the day 0.96% higher at $18.92. A total of
1.23 million shares were traded, which is below the daily average volume of
1.56 million. NPS Pharmaceuticals' shares have gained 42.79% in the last three
months, outperforming the S&P 500 which has gained 5.74% during the same
period. Furthermore, the stock is currently trading near its 52-week high of
$19.06. A free report on NPSP can be accessed by registering at:
Halozyme Therapeutics Inc.'s stock rose sharply on Monday. The company's
shares closed the day 2.70% higher at $7.24. A total of 1.79 million shares
were traded, which is above the daily average volume of 1.52 million. The
stock is trading below its 50-day moving average. In the last three months,
Halozyme Therapeutics' shares have advanced 19.87%, outperforming the S&P 500
which has gained 5.74% during the same period. Register with AAA Research
Reports and download research on HALO for free at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by a CFA. However, we are only human and are prone to
make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
SOURCE AAA Research Reports
Contact: Media Contact: Phone #: +1-(646)-396-9126
Press spacebar to pause and continue. Press esc to stop.